背景：HIK1083和MUC6已被用作免疫组织化学标记，以区分胃型腺癌（GTAC）与其他宫颈腺癌。我们旨在通过系统评价和荟萃分析评估其诊断准确性。
方法：从开始到2022年7月，检索了三个电子数据库，用于评估宫颈内膜GTAC与其他宫颈内膜腺癌中表达的所有研究。诊断准确性评估为灵敏度，特异性，正似然比(LR+)，负似然比(LR-)，诊断优势比(DOR)，和SROC曲线上的曲线下面积(AUC)。
结果：纳入了四项研究，共343例患者。HIK1083的敏感性=0.64，特异性=0.94，LR+=8.30，LR-=0.38，DOR=33.36，AUC=89.9%。MUC6的敏感性=0.51，特异性=0.74，LR+=1.96，LR-=0.71，DOR=3.48，AUC=72.8%。
结论：HIK1083作为GTAC的标志物显示出高特异性和低敏感性，总体准确性中等；MUC6表现出中等特异性和低敏感性，整体精度较低。
BACKGROUND: HIK1083 and
MUC6 have been used as immunohistochemical markers to differentiate gastric-type adenocarcinoma (GTAC) from other endocervical adenocarcinomas. We aimed to assess their diagnostic accuracy through a systematic
review and meta-analysis.
METHODS: Three electronic databases were searched from their inception to July 2022 for all studies assessing the expression in endocervical GTAC vs other endocervical adenocarcinomas. Diagnostic accuracy was assessed as sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR-), diagnostic odds ratio (DOR), and area under the curve (AUC) on SROC curves.
RESULTS: Four studies with 343 patients were included. HIK1083 showed sensitivity= 0.64, specificity= 0.94, LR+ =8.30, LR-= 0.38, DOR= 33.36, AUC= 89.9%.
MUC6 showed sensitivity= 0.51, specificity= 0.74, LR+ =1.96, LR-= 0.71, DOR= 3.48, AUC= 72.8%.
CONCLUSIONS: HIK1083 showed high specificity and low sensitivity as a marker of GTAC, with moderate overall accuracy;
MUC6 showed moderate specificity and low sensitivity, with low overall accuracy.
